Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
bendamustine
carfilzomib
multiple myeloma
phase 1/2 study
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
revised:
22
03
2021
received:
05
11
2020
accepted:
16
04
2021
pubmed:
29
6
2021
medline:
9
3
2022
entrez:
28
6
2021
Statut:
ppublish
Résumé
Combined therapy with carfilzomib, bendamustine, and dexamethasone was evaluated in this multicenter phase 1/2 trial conducted within the European Myeloma Network (EMN09 trial). Sixty-three patients with relapsed/refractory multiple myeloma who had received ≥2 lines of prior therapy were included. The phase 1 portion of the study determined the maximum tolerated dose of carfilzomib with bendamustine set at 70 mg/m On the basis of the phase 1 results, the recommended phase 2 dose for carfilzomib was 27 mg/m In heavily pretreated patients who have relapsed/refractory multiple myeloma, combined carfilzomib, bendamustine, and dexamethasone is an effective treatment option administered in the outpatient setting. Infection prophylaxis and attention to patients with cardiovascular predisposition are required.
Sections du résumé
BACKGROUND
Combined therapy with carfilzomib, bendamustine, and dexamethasone was evaluated in this multicenter phase 1/2 trial conducted within the European Myeloma Network (EMN09 trial).
METHODS
Sixty-three patients with relapsed/refractory multiple myeloma who had received ≥2 lines of prior therapy were included. The phase 1 portion of the study determined the maximum tolerated dose of carfilzomib with bendamustine set at 70 mg/m
RESULTS
On the basis of the phase 1 results, the recommended phase 2 dose for carfilzomib was 27 mg/m
CONCLUSIONS
In heavily pretreated patients who have relapsed/refractory multiple myeloma, combined carfilzomib, bendamustine, and dexamethasone is an effective treatment option administered in the outpatient setting. Infection prophylaxis and attention to patients with cardiovascular predisposition are required.
Substances chimiques
Oligopeptides
0
carfilzomib
72X6E3J5AR
Dexamethasone
7S5I7G3JQL
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3413-3421Subventions
Organisme : Onyx/Amgen
Organisme : Mundipharma Germany
Organisme : HOVON Foundation
Organisme : FoNeSa ONLUS
Informations de copyright
© 2021 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122-1128. doi:10.1038/leu.2013.313
Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27-38. doi:10.1016/S1470-2045(15)00464-7
Orlowski RZ, Moreau P, Niesvizky R, et al. Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk. 2019;19:522-530.e1. doi:10.1016/j.clml.2019.04.018
Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17:2734-2743. doi:10.1158/1078-0432.CCR-10-1950
Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327-1337. doi:10.1016/S1470-2045(17)30578-8
Ozegowski W, Krebs D. IMET 3393, (-[1-Methyl-5-bis-(β-chlorathyl)-aminobenzimidazolyl-(2)]-butter saurehydrochlorid, ein neues Zytostatikum aus der Reihi der Benzimidazol-Loste. Zbl Pharm. 1971;110:1013-1019.
Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132:205-212. doi:10.1007/s00432-005-0074-4
Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783-1792. doi:10.1158/0008-5472.CAN-06-2258
Surget S, Lemieux-Blanchard E, Maiga S, et al. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leuk Lymphoma. 2014;55:2165-2173. doi:10.3109/10428194.2013.871277
Hideshima T, Anderson KC. Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies. Semin Hematol. 2012;49:223-227. doi:10.1053/j.seminhematol.2012.04.006
Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;160:321-330. doi:10.1111/bjh.12129
Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 2013;3:e162. doi:10.1038/bcj.2013.58
Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014;123:985-991. doi:10.1182/blood-2013-08-521468
Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-152. doi:10.1056/NEJMoa1411321
Leleu X, Martin TG, Einsele H, et al. Role of proteasome inhibitors in relapsed and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19:9-22. doi:10.1016/j.clml.2018.08.016
Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817-2825. doi:10.1182/blood-2012-05-425934
Durie BGM. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc. 2007;82:516-517. doi:10.4065/82.4.516
Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113-3120. doi:10.1200/JCO.2005.04.7779
Mateos MV, Ocio EM, Sureda Balari A, et al. 653. Randomized phase 2 study of weekly carfilzomib 70 Mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple myeloma (RRMM) patients (GEM-KyCyDex) [abstract]. Blood. 2020;136(suppl 1):8-9. doi:10.1182/blood-2020-140934
Tessenow H, Holzvogt M, Holzvogt B, et al. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). J Cancer Res Clin Oncol. 2017;143:2049-2058. doi:10.1007/s00432-017-2439-x
Ludwig H, Delforge M, Facon T, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32:1542-1560. doi:10.1038/s41375-018-0040-1
Engelhardt M, Herget GW, Graziani G, et al. Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. Haematologica. 2018;103:755-758. doi:10.3324/haematol.2018.188516
Mey UJM, Brugger W, Schwarb H, et al. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma-a phase II trial. Br J Haematol. 2017;176:770-782. doi:10.1111/bjh.14481
Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133:1953-1963. doi:10.1182/blood-2018-09-874396
Moreau P, Kumar S, Boccia R, et al. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study). Leukemia. 2019;33:2934-2946. doi:10.1038/s41375-019-0480-2
Wester R, Van Der Holt B, Asselbergs E, et al. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica. 2019;104:2265-2273. doi:10.3324/haematol.2018.205476
Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953-964. doi:10.1016/S1470-2045(18)30354-1
Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016;30:1005-1017. doi:10.1038/leu.2015.356
Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27:1707-1714. doi:10.1038/leu.2013.29
Quach H, White D, Spencer A, et al. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemother Pharmacol. 2017;79:1067-1076. doi:10.1007/s00280-017-3287-8
Ponisch W, Moll B, Bourgeois M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol. 2013;139:1937-1946. doi:10.1007/s00432-013-1513-2
Bringhen S, Milan A, D’Agostino M, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib. A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019;286:63-74. doi:10.1111/joim.12882
Bringhen S, Milan A, Ferri C, et al. Cardiovascular adverse events in modern myeloma therapy-incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;103:1422-1432. doi:10.3324/haematol.2018.191288
Ponisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol. 2013;139:499-508. doi:10.1007/s00432-012-1339-3
Kaufman JL, Mina R, Jakubowiak AJ, et al. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium phase I study. Blood Cancer J. 2019;9:3. doi:10.1038/s41408-018-0154-8
Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688) [abstract]. Blood. 2019;134(suppl):LBA-6. doi:10.1182/blood-2019-132629
Bringhen S, Mina R, Cafro AM, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia. 2018;32:1803-1807. doi:10.1038/s41375-018-0024-1
Weisel K, Paner A, Engelhardt M, et al. Impact of elotuzumab plus pomalidomide and dexamethasone on health-related quality of life in patients with relapsed/refractory multiple myeloma enrolled in the ELOQUENT-3 study [abstract]. Blood. 2019;134(suppl 1):3480. doi:10.1182/blood-2019-122232
Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:7-13. doi:10.1016/S0140-6736(19)32556-5
Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104-2115. doi:10.1056/NEJMoa1817249
Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395:132-141. doi:10.1016/S0140-6736(19)32956-3
Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29-38. doi:10.1016/S0140-6736(19)31240-1
Baz RC, Martin TG, Lin HY, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127:2561-2568. doi:10.1182/blood-2015-11-682518
Pozzi S, Gentile M, Sacchi S, et al. Bendamustine, low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Leuk Lymphoma. 2017;58:552-559. doi:10.1080/10428194.2016.1205741
Garderet L, Kuhnowski F, Berge B, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018;132:2555-2563. doi:10.1182/blood-2018-07-863829
Palumbo A, Offidani M, Patriarca F, Petrucci MT, Cavo M. Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data. Leuk Lymphoma. 2015;56:559-567. doi:10.3109/10428194.2014.915545
Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016;128:2757-2764. doi:10.1182/blood-2016-09-692947
Rajkumar SV. Value and cost of myeloma therapy. Am Soc Clin Oncol Educ Book. 2018;38:662-666. doi:10.1200/EDBK_200867